Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 2,490,000 shares, a decrease of 22.7% from the February 13th total of 3,220,000 shares. Based on an average trading volume of 676,300 shares, the short-interest ratio is currently 3.7 days. Currently, 2.0% of the shares of the stock are sold short.

Alnylam Pharmaceuticals Stock Down 3.5 %

Shares of NASDAQ:ALNY opened at $244.30 on Wednesday. The company has a fifty day moving average of $255.73 and a 200-day moving average of $259.59. The company has a market capitalization of $31.63 billion, a PE ratio of -112.58 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,416,865. This represents a 81.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. The trade was a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 in the last three months. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Huntington National Bank increased its holdings in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Larson Financial Group LLC boosted its position in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 73 shares during the last quarter. Park Square Financial Group LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $28,000. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $33,000. Finally, OFI Invest Asset Management bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $35,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Canaccord Genuity Group increased their target price on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Chardan Capital reissued a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $304.26.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.